Loading
NASDAQHealthcareBiotechnology
Latest quote
$43.62
+$0.16 · +0.37%
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Previous close
$43.62
+$0.16 · +0.37%
After-hours
$43.62
$0.00 · 0.00%
Sep 11, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Day range
Current $43.62
52-week range
Current $43.62
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
38
Expensive
Sentiment
63
Bullish
Risk
41
Elevated Risk
Momentum
74
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Day range
Current $43.62
52-week range
Current $43.62
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cost of goods sold | — | — | — | 15K USD |
| Gross profit | — | — | — | −15K USD |
| Research and development | 94.79M USD | 60.94M USD | 28M USD | 9.12M USD |
| Selling, general, and administrative | 30.31M USD | 22.12M USD | 8.18M USD | 1.37M USD |
| Operating expenses | 125.1M USD | 83.06M USD | 36.18M USD | 10.35M USD |
| Interest income | 13.62M USD | 12.14M USD | 2.53M USD | — |
| Interest expense | — | — | — | 285K USD |
| Depreciation and amortization | 1.02M USD | 839K USD | 112K USD | 15K USD |
| Operating income | −125.1M USD | −83.06M USD | −36.18M USD | −10.37M USD |
| Net income | −111.48M USD | −78.31M USD | −34.79M USD | −10.65M USD |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI40.44M0.00%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 ETFIWM34.19M0.04%77.55B USD0.19%$288.89+0.41%
Vanguard Extended Market ETFVXF13.6M0.01%93.7B USD0.05%$237.76+0.68%
iShares Russell 2000 Growth ETFIWO11.87M0.08%14.32B USD0.24%$367.63+0.54%
iShares Biotechnology ETFIBB9.46M0.09%10.3B USD0.44%$202.93+0.14%
State Street SPDR S&P Pharmaceuticals ETFXPH9.41M1.59%591.91M USD0.35%$67.51-0.74%
Vanguard Russell 2000 ETFVTWO7.04M0.04%17.4B USD0.06%$116.76+0.36%
Schwab U.S. Small-Cap ETFSCHA5.99M0.03%22.32B USD0.03%$33.79+0.42%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
